Expert Q&A Presentations

Prostate Cancer



  • Daniel J. George, MD

    Daniel J. George, MD

    Daniel J. George, MD

    Medical Oncologist, Director of GU Oncology Duke Cancer Institute

    Dr Daniel George is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke University School of Medicine. He also has appointments in the Duke Clinical Research Institute and the Duke Cancer Institute where he is the Director of Genitourinary (GU) Oncology. He is an internationally recognized clinical researcher and thought leader in GU malignancies, with over 150 peer-reviewed publications. His areas of research include new drug development and biomarkers of GU cancers with an emphasis on signal transduction pathways and angiogenesis. Dr. George has led the Duke site for the Department of Defense (DOD) Prostate Cancer Clinical Trials Consortium since 2006, specializing in Phase I and II studies in prostate cancer. He is also the PI of the MaRCC registry in advanced renal cell carcinoma and Co-PI of IRONMAN, an international, multi-sponsor supported registry in advanced prostate cancer. Dr. George serves on the ASCO scientific committee for non-prostate cancer, the Alliance GU scientific committee, NCI GU Steering Committee and the NCI Renal Task Force. He also serves as a senior editor for Clinical Cancer Research and Clinical Advances in Hematology and Oncology.
  • Andrew J. Armstrong, MD, ScM, FACP

    Andrew J. Armstrong, MD, ScM, FACP

    Andrew J. Armstrong, MD, ScM, FACP

    Associate Professor of Medicine and Surgery

    Andrew J. Armstrong, MD, ScM, FACP, is an associate professor of medicine, surgery, pharmacology and cancer biology at Duke University, and is associate director of the Duke Cancer Institute Genitourinary Clinical Research Program. His work focuses on experimental therapeutics for patients with advanced genitourinary malignancies, with an emphasis on prostate cancer and the investigation of biomarkers of response and benefit. Dr Armstrong has developed numerous experimental agents in prostate and renal cell cancer, and is involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer. He co-chaired the Prostate Cancer Working Group 3 and is a leading member of the NCCN Prostate Cancer panel.